Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from June 3, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on September 1, 2026 — +7.3% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted
$42.06 Published $45.69 Target $45.12 Window close $51.46 Peak
$39.97 – $42.41Entry zone — fair-value band
$42.06Published — price the day we called it
$45.69Target — the price the thesis aimed for
$51.46Peak — highest point inside the window, not a realized return
$45.12Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 20 days.

At window close
+7.3%
realized, from the publication price to the last close inside the window
Peak gain
+22.3%
peak, from the publication price — not a realized return
S&P 500, same window
+1.3%
SPY over the identical days, dividend-adjusted
Window close
$45.12
last close inside the window, ended September 1, 2026
Peak price
$51.46
peak on July 29, 2026 — not a realized return
Days to target
20

The thesis — published June 3, 2026

Predicted growth
+10%
over the measurement window
Target price
$45.69
the price the thesis aimed for
Entry zone
$39.97 – $42.41
the fair-value band we waited for
Price at publication
$42.06
published June 3, 2026
Confidence
74%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Novo Nordisk gives steady healthcare exposure to the growing GLP-1 obesity market at a more reasonable price than many rivals. The new oral Wegovy release outside the U.S. is a clear commercial boost. A recent earnings shortfall, debt levels, and weak market momentum limit short-term upside, so the rebound case is measured, not aggressive.

Primary drivers

  • New oral Wegovy expands where the drug can be sold
  • Strong, lasting demand for obesity treatments
  • Lower price versus peers supports a modest rebound
  • Recent oversold drop gives clearer risk and reward levels

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals